由于没有预测HB4小麦收益, 生物塞雷斯农作物解决方案面临16%的库存下降. Bioceres Crop Solutions faced a 16% stock drop due to missed HB4 wheat earnings estimates.

由于其转基因HB4小麦的收益未达到预期, 阿根廷生物技术公司Bioceres Crop Solutions的股票下跌了近16%. Bioceres Crop Solutions, an Argentine biotech firm, faced a nearly 16% stock drop after its GMO HB4 wheat earnings missed estimates. 尽管美国批准了HB4种植,但CEO Federico Trucco表示,可能需要2至3年时间才能使小麦适应美国农民的需要。 Despite U.S. approval for HB4 cultivation, CEO Federico Trucco indicated it may take two to three years to adapt the wheat for American farmers. 该公司还必须解决对转基因生物小麦和高特许权使用费的关切,以加强其在阿根廷的市场存在,并有可能向其他国家出口。 The company must also address concerns about GMO wheat and high royalties to enhance its market presence in Argentina and potentially export to other countries.